Breaking News

Catalent Acquires Lyopan Technology

Catalent Pharma Solutions has entered into a license agreement with Pantec AG for the exclusive worldwide development rights to the Lyopan fast-dissolve technology for healthcare products.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

@font-face { font-family: “Cambria”; }@font-face { font-family: “Optima”; }p.MsoNormal, li.MsoNormal, div.MsoNormal { margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: “Times New Roman”; }div.Section1 { page: Section1; }Catalent Pharma Solutions has entered into a license agreement with Pantec AG for the exclusive worldwide development rights to the Lyopan fast-dissolve technology for healthcare products. The acquisition provides Catalent with ne...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters